[Pharmacoeconomic advantages of recombinant FSH vs urinary derived FSH].
Nowadays, the use of urinary FSH is essentially justified by a lower acquisition price compared to modern products generated by Biotechnology (recombinant FSH). However, the public price of a product is only one element of the total cost of a therapeutic regimen that must be taken into account in medical decision-making. This is the role of pharmacoeconomic studies including cost-effectiveness models, which allow proceeding to complex situational comparisons such as several attempts of Assisted Reproduction Techniques. Different models have been carried out and published in several countries and present consistently that recombinant FSH is more cost-effective that urinary derived FSH.
Beresniak
A
A
Serono international SA, 15, chemin des Mines, CH 1211, Genève 20, Suisse. ariel.beresniak@serono.com
D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D005260:Female; D005640:Follicle Stimulating Hormone / Q000191:economics* / Q000652:urine*; D006801:Humans; D011247:Pregnancy; D011994:Recombinant Proteins / Q000191:economics*; D012099:Reproductive Techniques / Q000191:economics
D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone
Avantages pharmaco-économiques de la FSH d'origine recombinante par rapport à la FSH d'origine urinaire.